The introduction of national guidelines has resulted in an increase of prophylactic antithrombotic prescribing in accordance with their contents. Conclusions: Initiating antithrombotic prescribing in newly diagnosed IHD patients can be predicted by patient gender, certain co-morbidity and main type of nitrate therapy. Furthermore, initiating antithrombotic prescribing was more likely after the introduction of national guidelines (OR 1.4, 95% CI 1.1–1.7). Male patients, patients with cardiovascular (other than IHD) and diabetic co-morbidity (OR 6.4, 95% CI 4.8–7.9 and OR 1.6, 95% CI 1.1–2.1, respectively) and patients using isosorbide mononitrate rather than isosorbide dinitrate as anti-ischaemic main therapy (OR 2.1, 95% CI 1.3–2.5) were most likely to be prescribed antithrombotic therapy. Results: Of the 2598 patients who met specified inclusion criteria for newly diagnosed IHD, approximately 35% was not prescribed any type of antithrombotic therapy. Statistically significant ( P<0.05) predictors were assessed using multivariable analysis considering patient, prescriber and medication characteristics. Therapeutic Category: CARDIOVASCULAR MEDICATIONS. ISOSORBIDE MONONITRATE TAB,SA has a VA Formualry status of Formulary Item and is within VA copay tier level 1. Initiation of antithrombotic therapy was likewise identified using ATC codes B01AA and B01AC (oral anticoagulants and thrombocyte aggregation inhibitors), prescribed within 6 months following the first nitrate prescription. ISOSORBIDE MONONITRATE TAB,SA (Formulary Item) is an item listed by VA within the class ANTIANGINALS. trinitrate 12.1 C01DA08 isosorbide dinitrate 12.1 C02 Antihypertensives C02A. IHD patients were identified using as a marker multiple nitrate prescriptions indicating chronic use. ATC code ATC group/medicine or item Section C01C Cardiac stimulants excl. Design and setting: A retrospective case control study was performed using pharmacy prescription data from 120,000 Dutch patients over a 5-year period. Objectives: Assessment of predictors for initiating prophylactic antithrombotic prescribing for patients newly diagnosed with ischaemic heart disease (IHD) and the impact of the introduction of national guidelines.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |